Pulmonary vascular diseases

1. Therapy
2. Different types of delivery
3. Medical management of right heart failure
4. Non-medical therapies
5. Surgery/balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (CTEPH)
6. Pulmonary artery denervation

Indications for pulmonary rehabilitation

1. Indications for institution of palliative care
2. End-of-life relief of symptoms by:
3. Pharmacological interventions
4. High-flow nasal oxygen
5. Discussing end-of-life decisions with patients and their relatives

–

1. Indications for assisted ventilation
2. Effects of mechanical ventilation on pulmonary haemodynamics and heart function

1. Principles of evaluation for lung transplantation
2. Risk and particularities of lung transplantation in patients with PVD
3. Severity grading of lung diseases with respect to referring a patient to a transplant centre
4. Extracorporeal membrane oxygenation/right ventricular assist device

1. Management of right heart failure
2. Management of cardiac arrhythmias
3. Management of acute pulmonary embolism (PE), pulmonary embolism response team (PERT)
4. Cardiopulmonary arrest in a patient with pulmonary arterial hypertension (PAH)

1. Differential diagnosis of PVD and PE
2. Haemoptysis
3. Dyspnoea
4. Thoracic pain
5. PE
6. Haemoptysis
7. Dyspnoea
8. Thoracic pain
9. Massive acute pulmonary embolism
10. Management of shock related to right heart failure
11. Early identification of chronic thromboembolism

1. Severe PH sub-phenotypes in COPD
2. Polycythaemia
3. Management of cor pulmonale

1. Signs and symptoms associated with sleep-disordered breathing
2. Recognition of sleep-disorder breathing as a cause of moderate PH
3. Physiology and pathophysiology of sleep apnoea syndromes relevant to acute respiratory failure

1. Recognition of Sarcoidosis and its association with PH
2. Recognition of PH as a poor prognostic factor in sarcoidosis
3. Effects of drug therapy on PH

1. Prognostic factors associated with ILD and PVD
2. Classification of ILD
3. Limitations/dangers of PAH therapies in ILD

1. ILD associated with CTD
2. Prognostic factors associated with ILD
3. List treatment choices

Identification of causes of PVD from drug history

1. Anorexigens
2. Amphetamines
3. Selected tyrosine kinase inhibitors
4. Interferon
5. Chemotherapeutic agents (alkylating agents)

1. Identification of PE
2. Differential diagnosis of PE
3. Aetiology of PE
4. Pulmonary Embolism Severity Index score and risk stratification of PE
5. Management of PE without acute hemodynamic compromise
6. Conditions/diseases associated with an increased risk of thromboembolic disease
7. Current indications for prophylaxis against thromboembolic disease
8. Adverse effects associated with anticoagulation therapy
9. Interpretation of blood cell counts and coagulation laboratory tests
10. Drug indications and their appropriate dosages
11. Willingness to consider potential candidates for prophylaxis against thromboembolic disease
12. Prophylaxis against thromboembolic disease
13. Conditions/diseases associated with an increased risk of thromboembolic disease
14. Adverse effects associated with anticoagulation therapy
15. Interpretation of coagulation laboratory tests
16. Drug indications and their appropriate dosages
17. Genetic risk factors for thrombosis and their impact on clinical decisions
18. Indications for targeted thrombosis (interventional radiology) and embolectomies
19. Diagnosis and management of CTEPH
20. Indications for thrombophilia screening
21. ndications for inferior vena cava filter placement
22. Follow-up after PE presentation, e.g. risk scoring (such as DASH) to discuss the risks/benefits of anticoagulation therapy

1. Pathophysiology of PH
2. Pharmacological treatment of PH according to underlying disease
3. Diagnosis of PH and cor pulmonale
4. Risk stratification
5. Translating national and international management guidelines to an individual patient
6. Appropriate decisions for referral and transfer to specialised referral centres
7. Prognosis of patients with PH in acute care settings
8. Indications for systemic pharmacotherapy
9. Indications for combination therapy
10. Indications for intravenous therapy
11. Chronic monotherapy or combination systemic therapy
12. Institute general therapeutic and supportive measures

1. Pulmonary haemorrhage and haemoptysis
2. Differential diagnoses, diagnostic steps and therapeutic options for pulmonary haemorrhage and haemoptysis
3. Triage by severity
4. Indications for radiological evaluation
5. Indications for bronchoscopic evaluation

1. Symptoms of AV malformation
2. Diseases associated with AV malformation (e.g. hereditary haemorrhagic telangiectasia)
3. Diagnostic strategies when AV malformation is suspected
4. Therapeutic interventions

1. Differentiate between cardiac and pulmonary disease as a cause of acute respiratory failure
2. Recognition of cardiac disease as an aetiology of PH
3. Monitoring cardiac dysfunction in PVD patients via clinical, laboratorial, functional, echocardiographic and radiological means
4. Principles of invasive cardiovascular monitoring (e.g. Swan-Ganz catheterisation)
5. Cardiovascular effect of positive pressure ventilation
6. Congenital heart diseases and Eisenmenger syndrome

1. Portopulmonary hypertension
2. Hepatopulmonary syndrome

1. PVD in patients with past or current haematological conditions
2. Thrombophilia as a potential sign of PVD

1. CTD as a cause of PH
2. Symptoms and clinical presentation
3. Pathophysiology of CTD and PH
4. Differential diagnosis and optimal testing
5. Optimal treatment
6. Prognostication of identified CTD

Familial occurrence of PH

1. High-altitude as a cause of pulmonary oedema (HAPE)
2. Pathophysiology, symptoms and clinical presentation of high-altitude sickness
3. Performance of tests to establish the diagnosis
4. Preventive measures